Cost effectiveness of infant vaccination for rotavirus in Canada

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 23, Issue 2, 2012, Pages 71-77

  Coyle, Doug ^a   Coyle, Kathryn ^b   Bettinger, Julie A ^c   Halperin, Scott A ^d   Vaudry, Wendy ^e   Scheifele, David W ^c   Le Saux, Nicole ^f  

^a UNIVERSITY OF OTTAWA   (Canada)

^b Applied Health Economics Research Unit   (Canada)

^c BC CHILDREN S HOSPITAL   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e STOLLERY CHILDREN S HOSPITAL   (Canada)

^f CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

Cost effectiveness; Rotavirus; Vaccination

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CHILD; CONSULTATION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HUMAN; HUMAN ROTAVIRUS; PRESCHOOL CHILD; QUALITY ADJUSTED LIFE YEAR; ROTAVIRUS INFECTION; VACCINATION;

EID: 84864857016     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2012/327054     Document Type: Article

References (47)

1. Parashar UD, Gibson CJ, Bresee JS, et al. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006;12:304-6.
2. World Health Organization Weekly Epidemiological Record 2008; 83(47), 27 November 2008. 〈www.who.int/nuvi/rotavirus/en/〉 (Accessed October 20, 2009).
3. Ford-Jones EL, Wang E, Petric M, et al. Hospitalization for community-acquired, rotavirus-associated diarrhea. Arch Pediatr Adolesc Med 2000;154:578-85.
4. Rivest P, Proulx M, Lonergan G, et al. Hospitalisations for gastroenteritis: The role of rotavirus. Vaccine 2004;22:2013-7. (Pubitemid 38581071)
5. Bilcke J, Beutels P. Reviewing the cost-effectiveness of rotavirus vaccination: The importance of uncertainty in the choice of data sources. Pharmacoeconomics 2009;27:281-97.
6. Widdowson MA, Meltzer ML, Zhang X, et al. Cost-effectiveness and potential impact of rotavirus vaccination in the United States. Pediatrics 2007;119:684-97. (Pubitemid 46556667)
7. Jacobs P, Shane LG, Fassbender K, et al. Economic analysis of rotavirus-associated diarrhea in the metropolitan Toronto and Peel regions of Ontario. Can J Infect Dis 2002;13:167-74. (Pubitemid 34855525)
8. Scheifele D. IMPACT after 17 years: Lessons learned about successful networking. Paediatr Child Health 2009;14:33-5.
9. Health Canada. Notice of decision for Rotarix. 2008. 〈www.hc-sc.gc. ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2008-rotarix-109624-eng. php〉 (Accessed April 30, 2012).
10. Health Canada. Notice of decision for RotaTeq. 2006. 〈www.hc-sc.gc. ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd-smd-2007-rotateq-100399-eng. php〉 (Accessed April 30, 2012).
11. Vesikari T, Karvonen A, Prymula R, et al. Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: Randomized, double-blind controlled study. Lancet 2007;370:1757-63. (Pubitemid 350137490)
12. Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatr Infect Dis J 2004;23:937-43. (Pubitemid 40812781)
13. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33. (Pubitemid 43048948)
14. Salinas B, Schael IP, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX 4414. Pediatr Infect Dis J 2005;24:807-16.
15. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22. (Pubitemid 43048947)
16. Lieu T, Meltzer MI, Messonnier ML. Guidance for health economics studies. The Advisory Committee on Immunization Practices. ACIP 2007. 〈www.cdc.gov/vaccines/recs/acip/downloads/economics-studies-guidance. pdf〉 (Accessed April 30, 2012).
17. Erickson LJ, De Wals P, Farand L. An analytical framework for immunization programs in Canada. Vaccine 2005;23:2470-6.
18. Canadian Agency for Drugs and Technologies [CADTH]. Guidelines for economic evaluation of pharmaceuticals in Canada. 3rd Edition, Ottawa: CADTH, 2006.
19. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998;13:397-409. (Pubitemid 28140699)
20. Tambay JL, Catilin G. Sample design of the National Population Health Survey. Health Reports (Statistics Canada, Catalogue 82-003) 1995;7:29-38.
21. Statistics Canada. Life Tables, Canada, Provinces and Territories, 2000 to 2002. Catalogue No. 84-537-XIE. 〈www.statcan.gc.ca/pub/84-537-x/4064441- eng.htm〉 (Accessed April 30, 2012).
22. Bilcke J, van Damme P, van Ranst M et al. Estimating the incidence of symptomatic rotavirus infections: A systematic review and meta-analysis. PLoS ONE 2009;4:e6060,1-e6060,10.
23. Gurwith M, Wenman W, Hinde D, et al. A prospective study of rotavirus infection in infants and young children. J Infect Dis 1981;144:218-24. (Pubitemid 11020384)
24. Brisson M, Sénécal M, Drolet M, Mansi JA. Health-related quality of life lost to rotavirus-associated gastroenteritis in children and their parents: A Canadian prospective study. Pediatr Infect Dis J 2010;29:73-5.
25. Lorgelly PK, Joshi D, Iturriza Gomara M, et al. Exploring the cost effectiveness of an immunization programme for rotavirus gastroenteritis in the United Kingdom. Epidemiol Infect 2008;136:44-55.
26. Ward RL, Bernstein DI. Protection against rotavirus disease after natural rotavirus infection. US Rotavirus Vaccine Efficacy Group. J Infect Dis. 1994;169:900-4. (Pubitemid 24102131)
27. Kilgore PE, Holman RC, Clarke MJ, et al. Trends of diarrheal disease-associated mortality in U.S. children, 1968 through 1991. JAMA 1995;274:1143-8.
28. World Health Organization vaccine preventable diseases: Monitoring system. 2008 Global Summary. 〈www.who.int/immunization/documents/en/〉 (Accessed October 20, 2009).
29. Ontario Ministry of Health and Long-Term Care. Ontario drug benefit formulary/comparative drug index Edition 41. Toronto: Ontario Ministry of Health and Long-Term Care; 2008. 〈www.health.gov.on.ca/english/providers/program/ drugs/formulary/edition-41.pdf〉 (Accessed April 30, 2012).
30. Bank of Canada. Bank of Canada inflation calculator. Ottawa: Bank of Canada; 2012. 〈www.bankofcanada.ca/rates/related/inflation-calculator/ 〉 (Accessed April 30, 2012).
31. Mast TC, Walter EB, Bulotsky M, et al. Burden of childhood rotavirus disease on health systems in the United States. Pediatr Infect Dis J 2010;29:e19-25.
32. McDermid AK, Le Saux NM, Bettinger J, et al. Rotavirus serotypes: Results from an impact emergency department study [Abstract P055]. 9th Canadian Immunization Conference. Quebec City, December 5 to 8, 2010. Can J Infect Dis Med Microbiol 2010;21:198.
33. Ontario Ministry of Health and Long-Term Care. Ontario health insurance (OHIP) schedule of benefits and fees. Toronto: Ontario Ministry of Health and Long-Term Care; October 2010.
34. Bauch CT, Anonychuk AM, Pham BZ, Gilca V, Duval B, Krahn MD. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine 2007;25:8536-48. (Pubitemid 350192045)
35. Moore D, Bigham M, Patrick D. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia. Can Commun Dis Rep 2003;29:97-104.
36. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17:479-500. (Pubitemid 30398806)
37. Sapsford R. Deputy Minister's response to the investigation into the Ministry of Health and Long-Term Care's decision-making concerning the funding of Avastin for colorectal cancer patients. Letter dated August 26, 2009.
38. Tate J, Cortese M, Payne DC, et al. Uptake, impact, and effectiveness of rotavirus vaccination in the United States - review of the first 3 years of post-licensure data. Pediatr Infect Dis 2011;30:S56-60.
39. Quintanar-Solares M, Yen CY, Esparza-Aguilar M, et al. Impact of rotavirus vaccination on diarrhea-related hospitalizations among children <5 years of age in Mexico. Pediatr Infect Dis 2011;30:S11-15.
40. Jit M, Bilcke J, Mangen M-JJ et al. The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe, Vaccine 2009:27;6121-8.
41. Centers for Disease Control and Prevention (CDC). Delayed onset and diminished magnitude of rotavirus activity - United States, November 2007-May 2008. MMWR Morb Mortal Wkly Rep 2008;57:697-700.
42. Woodin KA, Redwald LE, Humiston SG, et al. Physician and parent opinions. Are children becoming pincushions from immunizations? Arch Pediatr Adolesc Med 1995;149:845-9.
43. Bernstein DI, Glass RI, Rodgers G, Davidson BL, Sack DA. Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 1995;273:1191-6.
44. Dennehy PH. Safety and efficacy of an oral tetravalent rhesus rotavirus vaccine (RRV-TV) in healthy infants. Pediatr Res 1994;35:1052.
45. Le Saux N, Bettinger J, Halperin S, Vaudry V, Scheifele D, for members of the Canadian Immunization Monitoring Program, Active (IMPACT). Hospital acquired rotavirus infections: Burden in Canadian paediatric hospitals. J Inf Prevention 2011:12:159-62.
46. Piednoir E, Bessaci K, Bureau-Chalot F, et al. Economic impact of healthcare-associated rotavirus infection in a paediatric hospital. Hosp Infect 2003;55:190-5. (Pubitemid 37554909)
47. Grimwood K, Lambert SB, Milne RJ. Rotavirus infections and vaccines: Burden of illness and potential impact of vaccination. Paediatr Drugs. 2010;12:235-56.